Stoke Therapeutics Inc (STOK) is a Healthcare · Biotechnology company listed on NASDAQ. Price $28.53 (-1.38%), Market cap $1.94B, 52-week low–high $8.93 ~ $38.35.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of
Financial statements, price targets, institutional (13F) holdings and related news for Stoke Therapeutics Inc are updated in real time on BlackAll Trade.
Stoke Therapeutics Inc trades at $28.53 (-1.38%). Real-time quotes and charts are available on BlackAll Trade.
Stoke Therapeutics Inc has a market cap of about $1.94B.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear